(BVI) Bureau Veritas - Overview
Sector: Industrials | Industry: Consulting Services | Exchange: PA (France) | Market Cap: 12.074m EUR | Total Return: 5.6% in 12m
Testing, Inspection, Certification, Auditing, Compliance
Total Rating 61
Safety 94
Buy Signal 0.09
Consulting Services
Industry Rotation: -3.2
Industry Rotation: -3.2
Market Cap:
14.2B
Avg Turnover: 29.8M EUR
Avg Turnover: 29.8M EUR
ATR:
2.48%
Peers RS (IBD): 61.1
Peers RS (IBD): 61.1
Risk 5d forecast
Volatility20.6%
Rel. Tail Risk-4.96%
Reward TTM
Sharpe Ratio0.10
Alpha-8.00
Character TTM
Beta0.420
Beta Downside0.260
Drawdowns 3y
Max DD20.96%
CAGR/Max DD0.24
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: BVI Bureau Veritas
Bureau Veritas SA (BVI) provides laboratory testing, inspection, and certification services across diverse sectors. The companys business model involves verifying compliance with regulatory or self-imposed standards for products, assets, and management systems, issuing compliance reports.
Its operations are divided into six segments, including Marine & Offshore and Agri-Food & Commodities. The testing, inspection, and certification (TIC) sector is characterized by a high degree of regulation and technical expertise requirements.
BVI serves a wide range of industries, such as construction, oil and gas, and consumer products, operating globally in approximately 140 countries. This extensive geographic reach is common for major TIC providers.
To gain a deeper understanding of BVIs performance, consider exploring its historical data on ValueRay.
- Global trade volume impacts inspection and certification demand
- Regulatory changes create new compliance service opportunities
- Commodity price volatility affects Agri-Food & Commodities segment
- Infrastructure spending drives Buildings & Infrastructure revenue
- Labor costs influence service delivery profitability
Piotroski VR‑10 (Strict)
10.0
| Net Income: 1.16b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.24 > 0.02 and ΔFCF/TA 7.30 > 1.0 |
| NWC/Revenue: 8.99% < 20% (prev 12.49%; Δ -3.50% < -1%) |
| CFO/TA 0.28 > 3% & CFO 1.96b > Net Income 1.16b |
| Net Debt (2.07b) to EBITDA (2.22b): 0.93 < 3 |
| Current Ratio: 1.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (445.7m) vs 12m ago -2.73% < -2% |
| Gross Margin: 43.06% > 18% (prev 0.29%; Δ 4.28k% > 0.5%) |
| Asset Turnover: 186.8% > 50% (prev 151.6%; Δ 35.23% > 0%) |
| Interest Coverage Ratio: 8.22 > 6 (EBITDA TTM 2.22b / Interest Expense TTM 199.1m) |
Altman Z''
3.78
| A: 0.16 (Total Current Assets 3.31b - Total Current Liabilities 2.16b) / Total Assets 7.06b |
| B: 0.23 (Retained Earnings 1.66b / Total Assets 7.06b) |
| C: 0.24 (EBIT TTM 1.64b / Avg Total Assets 6.85b) |
| D: 0.32 (Book Value of Equity 1.71b / Total Liabilities 5.31b) |
| Altman-Z'' Score: 3.78 = AA |
Beneish M
-3.41
| DSRI: 0.78 (Receivables 1.94b/1.94b, Revenue 12.80b/10.07b) |
| GMI: 0.68 (GM 43.06% / 29.18%) |
| AQI: 1.01 (AQ_t 0.42 / AQ_t-1 0.41) |
| SGI: 1.27 (Revenue 12.80b / 10.07b) |
| TATA: -0.11 (NI 1.16b - CFO 1.96b) / TA 7.06b) |
| Beneish M-Score: -3.41 (Cap -4..+1) = AA |
What is the price of BVI shares?
As of April 14, 2026, the stock is trading at EUR 27.11 with a total of 829,481 shares traded.
Over the past week, the price has changed by +2.92%, over one month by -3.80%, over three months by -0.18% and over the past year by +5.59%.
Over the past week, the price has changed by +2.92%, over one month by -3.80%, over three months by -0.18% and over the past year by +5.59%.
Is BVI a buy, sell or hold?
Bureau Veritas has no consensus analysts rating.
What are the forecasts/targets for the BVI price?
| Analysts Target Price | - | - |
Bureau Veritas (BVI) - Fundamental Data Overview
as of 14 April 2026
Market Cap USD = 14.16b (12.07b EUR * 1.1725 EUR.USD)P/E Trailing = 20.771
P/E Forward = 17.6678
P/S = 1.8071
P/B = 7.0566
P/EG = 2.0545
Revenue TTM = 12.80b EUR
EBIT TTM = 1.64b EUR
EBITDA TTM = 2.22b EUR
Long Term Debt = 2.39b EUR (from longTermDebt, last quarter)
Short Term Debt = 347.9m EUR (from shortTermDebt, last quarter)
Debt = 3.43b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.07b EUR (from netDebt column, last quarter)
Enterprise Value = 14.14b EUR (12.07b + Debt 3.43b - CCE 1.37b)
Interest Coverage Ratio = 8.22 (Ebit TTM 1.64b / Interest Expense TTM 199.1m)
EV/FCF = 8.47x (Enterprise Value 14.14b / FCF TTM 1.67b)
FCF Yield = 11.81% (FCF TTM 1.67b / Enterprise Value 14.14b)
FCF Margin = 13.04% (FCF TTM 1.67b / Revenue TTM 12.80b)
Net Margin = 9.04% (Net Income TTM 1.16b / Revenue TTM 12.80b)
Gross Margin = 43.06% ((Revenue TTM 12.80b - Cost of Revenue TTM 7.29b) / Revenue TTM)
Gross Margin QoQ = 5.32% (prev 23.27%)
Tobins Q-Ratio = 2.00 (Enterprise Value 14.14b / Total Assets 7.06b)
Interest Expense / Debt = 1.79% (Interest Expense 61.6m / Debt 3.43b)
Taxrate = 35.08% (146.9m / 418.7m)
NOPAT = 1.06b (EBIT 1.64b * (1 - 35.08%))
Current Ratio = 1.53 (Total Current Assets 3.31b / Total Current Liabilities 2.16b)
Debt / Equity = 2.01 (Debt 3.43b / totalStockholderEquity, last quarter 1.71b)
Debt / EBITDA = 0.93 (Net Debt 2.07b / EBITDA 2.22b)
Debt / FCF = 1.24 (Net Debt 2.07b / FCF TTM 1.67b)
Total Stockholder Equity = 1.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.89% (Net Income 1.16b / Total Assets 7.06b)
RoE = 68.54% (Net Income TTM 1.16b / Total Stockholder Equity 1.69b)
RoCE = 40.11% (EBIT 1.64b / Capital Employed (Equity 1.69b + L.T.Debt 2.39b))
RoIC = 25.65% (NOPAT 1.06b / Invested Capital 4.14b)
WACC = 6.07% (E(12.07b)/V(15.51b) * Re(7.46%) + D(3.43b)/V(15.51b) * Rd(1.79%) * (1-Tc(0.35)))
Discount Rate = 7.46% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -1.37%
[DCF] Terminal Value 88.20% ; FCFF base≈1.44b ; Y1≈1.77b ; Y5≈3.02b
[DCF] Fair Price = 188.6 (EV 85.73b - Net Debt 2.07b = Equity 83.67b / Shares 443.7m; r=6.07% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -7.10 | EPS CAGR: 0.0% | SUE: 0.0 | # QB: 0
Revenue Correlation: 47.67 | Revenue CAGR: 10.62% | SUE: 0.00 | # QB: 0
EPS current Year (2026-12-31): EPS=1.56 | Chg7d=-0.003 | Chg30d=-0.009 | Revisions Net=-3 | Growth EPS=+10.0% | Growth Revenue=+5.0%
EPS next Year (2027-12-31): EPS=1.70 | Chg7d=-0.002 | Chg30d=-0.006 | Revisions Net=-1 | Growth EPS=+8.6% | Growth Revenue=+6.2%
[Analyst] Revisions Ratio: -0.43 (2 Up / 5 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.1% (Discount Rate 7.9% - Earnings Yield 4.8%)
[Growth] Growth Spread = +3.1% (Analyst 6.2% - Implied 3.1%)